JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus

• Status: Completed
• Trial end date: 2020-04-17
• Target enrollment: 0
• Participant gender: All

Summary

To monitor the safety profile and effectiveness of Empagliflozin in Korea patients with type 2 diabetes mellitus in a routine clinical practice setting

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Boehringer Ingelheim
• Treatments: Empagliflozin

Criteria

Inclusion criteria:

1. Patients who have been started on JARDIANCE® in accordance with the approved label in Korea

2. Age = 19 years at enrolment

3. Patients who have signed on the data release consent form

Exclusion criteria:

1. Known hypersensitivity to empagliflozin or any of its excipients

2. Patients with type 1 diabetes or for the treatment of diabetic ketoacidosis

3. Patients with persistent estimated Glomerular Filtration Rate <60 mL/min/1.73 m2,end stage renal disease or on dialysis

4. Patients with rare hereditary conditions of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption

5. Patients for whom empagliflozin is contraindicated according local label of JARDIANCE®